NeurogesX, Inc. NGX-1998 Phase 2 Study Data to be Presented at World Congress on Pain

Published: Jul 17, 2012

SAN MATEO, Calif., July 16, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that it plans to present data from its Phase 2 study on NGX-1998 at the 14th World Congress on Pain, to be held August 27-31, 2012, at the Milano Convention Centre in Milan, Italy. NGX-1998 is the Company's next generation liquid formulation of prescription strength capsaicin.

Back to news